FOLH1 and cancer: Some of these limitations can be overcome by the application of bispecific antibodies that can spontaneously bind to both the poly ethylene glycol (PEG) coated nanoparticles and cancer specific antigens such as prostate specific membrane antigen (PSMA) or epidermal growth factor receptor (EGFR).